VirtualCareFinder may earn a commission when you visit a provider through our links.
2026 Regulatory Update: Compounded GLP-1 Availability
The FDA removed semaglutide and tirzepatide from its drug shortage list in 2025, which significantly restricted compounding pharmacies from producing bulk compounded versions of these medications. Several telehealth platforms have updated their offerings as a result — some have shifted toward brand-name pathways, and a few have paused compounded programs. Pricing and medication availability listed below reflect information as of May 2026; verify directly with each provider before enrolling.
How GLP-1 Telehealth Programs Work
GLP-1 receptor agonists — medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — have reshaped weight management. Telehealth platforms now offer remote consultations, prescriptions, medication delivery, and ongoing clinical support for patients seeking these treatments.
The programs vary significantly in what they charge, which medications they prescribe, whether they accept insurance, and how many states they cover. This guide breaks down seven leading programs side by side so you can make an informed decision.
What to Evaluate When Comparing Programs
Before committing to any GLP-1 telehealth program, assess these factors:
Medication type. Some programs prescribe brand-name FDA-approved medications (Wegovy, Zepbound). Others offer compounded semaglutide or tirzepatide — custom-prepared versions that are often cheaper but lack the same regulatory oversight. A few offer both.
Insurance support. Insurance coverage for GLP-1 medications is inconsistent across plans and states. Programs that handle prior authorizations and appeals can save significant time and money.
Clinical quality. Look for programs staffed by licensed physicians or nurse practitioners who conduct thorough evaluations — not just questionnaire-based approvals.
Ongoing support. Programs that include nutritional guidance, coaching, lab work, and regular check-ins tend to produce better outcomes than prescription-only services.
State availability. Not all programs operate in all 50 states. Verify coverage before signing up.
Side-by-Side Comparison
| Feature | Found | Calibrate | Ro | Hims & Hers | WW Clinic | Mochi Health | Sprout Health |
|---|---|---|---|---|---|---|---|
| Brand-Name GLP-1 | Y | Y | Y | N | ~ | Y | N |
| Compounded GLP-1 | Y | N | Y | Y | Y | Y | Y |
| Insurance Support | Y | Y | Y | N | ~ | Y | N |
| Monthly Cost (Compounded) | ~$99-$149 | N/A | ~$99+ | ~$79-$199 | ~$99+ | ~$79-$149 | $249-$299 |
| Coaching Included | Y | Y | ~ | N | Y | ~ | N |
Detailed Reviews
Compare GLP-1 providers by state, insurance, and price
Browse GLP-1 providersCompare GLP-1 providers by state, insurance, and price
Browse GLP-1 providersHow to Choose the Right Program
If insurance coverage is your top priority
Start with Calibrate or Ro. Both have established insurance workflows and prior authorization support. Calibrate is the stronger choice if you want brand-name medications exclusively.
If budget is your main concern
Hims & Hers and Mochi Health offer the most competitive pricing on compounded GLP-1 medications. WW Clinic also provides affordable options with added behavioral support.
If you want comprehensive support beyond medication
Found and Calibrate offer the most robust coaching and behavioral programs. Found is more flexible; Calibrate is more structured.
If you want flexibility without a long commitment
Ro offers a good balance of options without requiring a minimum commitment period.
If you want predictable pricing as you escalate doses
Sprout Health offers a price-lock guarantee — your monthly cost stays fixed at $249 (semaglutide) or $299 (tirzepatide) regardless of dose. This makes it increasingly cost-competitive over a full titration schedule compared to platforms that charge more at higher doses.
GLP-1 Titration and What to Expect
GLP-1 medications are started at a low dose and increased gradually over several months to minimize side effects and allow the body to adjust. The titration schedule for semaglutide (Wegovy) is a common reference point:
- Weeks 1–4: 0.25 mg/week (starting dose — not therapeutic, tolerance-building)
- Weeks 5–8: 0.5 mg/week
- Weeks 9–12: 1.0 mg/week
- Weeks 13–16: 1.7 mg/week
- Week 17+: 2.4 mg/week (maintenance dose)
Most patients do not notice significant weight loss effects until doses reach the 1.0 mg range or higher. Early weeks are primarily about tolerance. Rushing the titration schedule is a common cause of side effects — reputable programs will hold at a dose longer if side effects are significant.
Tirzepatide (Zepbound) follows a similar stepwise escalation starting at 2.5 mg/week and progressing to a maximum of 15 mg/week over 20+ weeks.
Managing Side Effects
Side effects are most common during dose escalation and typically diminish once you stabilize at a maintenance dose. Understanding them in advance — and knowing what your program offers for support — is important.
Nausea affects 20–40% of patients and is the most common reason for discontinuation. Strategies that help: eating smaller meals, eating slowly, avoiding high-fat or spicy foods, staying hydrated, and taking the injection before bed so nausea peaks during sleep. Anti-nausea medications (ondansetron, ginger supplements) can be prescribed by your provider.
Constipation is often overlooked but affects a significant portion of users. Proactive management with increased fiber, hydration, and stool softeners is more effective than reactive treatment.
Fatigue and headache are common in early weeks and usually resolve. These are often related to reduced caloric intake rather than the medication directly.
Muscle loss is a significant concern with rapid weight loss. Programs that include nutritional guidance emphasizing protein intake (0.7–1g per pound of body weight) and strength training substantially reduce this risk.
Evaluate each program's side effect support: How easy is it to reach a provider when you have a problem? Do they offer dose holds, titration adjustments, or adjunctive medication? Programs with poor access for side effect management drive higher discontinuation rates.
Important Considerations
Compounded vs. brand-name medications. Compounded semaglutide and tirzepatide are not FDA-approved in the same way as Wegovy or Zepbound. They became widely available when both drugs were listed on the FDA drug shortage list, allowing compounding pharmacies to produce them at scale. The FDA removed semaglutide and tirzepatide from that list in 2025, substantially restricting bulk compounding going forward. Programs built around compounded medications have had to adapt — some have shifted to brand-name pathways, others have paused enrollment. If low cost was your reason for choosing a compounded program, confirm with the provider that the program is still active and that pricing has not changed.
Medical evaluation quality. Any reputable program conducts a thorough medical evaluation before prescribing. If a program offers a prescription based solely on a brief questionnaire, that is a warning sign.
Side effect management. GLP-1 medications commonly cause nausea, constipation, and other GI side effects, especially during dose titration. Confirm that your program provides accessible support for managing side effects.
Long-term planning. GLP-1 medications are most effective as long-term treatment. Discuss with your provider what happens if you stop the medication and what a sustainable plan looks like. Clinical data consistently shows that most patients regain a significant portion of weight after discontinuing GLP-1 medications unless they have made lasting lifestyle changes. Programs that integrate behavioral coaching and nutritional education position patients better for sustainable outcomes.
Compare GLP-1 Providers on VirtualCareFinder
Browse all GLP-1 telehealth providers on VirtualCareFinder to compare programs by state, insurance acceptance, pricing, and included services. You can filter by location — for example, GLP-1 providers in Texas or GLP-1 providers in California — to find programs available where you live.